Androgen receptor (AR) signaling affects response to BRAF/MEK inhibitor therapy in both males and females with melanoma, researchers from The University of Texas MD Anderson Cancer Center showed in a study published today ...
Jun 15, 2022
0
51
Moles and melanomas are both skin tumors that come from the same cell called melanocytes. The difference is that moles are usually harmless, while melanomas are cancerous and often deadly without treatment. In a study published ...
Nov 23, 2021
0
33
Looking to understand why some brain tumors with a specific mutation can start to reject drugs commonly used to treat them, CU Cancer Center member Jean Mulcahy Levy, MD, led researchers from institutions around the country—including ...
Sep 15, 2021
0
34
Combining chemotherapy and BRAF oncogene inhibitors is an effective strategy for fighting metastatic melanoma, the leading cause of death from skin cancer in the world. This has been demonstrated in a study by researchers ...
Jul 13, 2021
0
2
Patients with advanced colorectal cancer may be spared from a toxic side effect caused by a type of targeted therapy used to treat the cancer with the help of another drug normally used to treat melanoma, according to a study ...
Apr 28, 2021
0
10
Advanced melanoma is one of the deadliest types of cancer, with a 5-year survival rate of only 27% for patients with distant metastases. Recent advances in targeted therapies and immunotherapies have greatly improved patient ...
Mar 2, 2021
0
12
A new study led by researchers at the University of Kentucky Markey Cancer Center and UK Department of Pharmacology and Nutritional Sciences demonstrates the potential benefit of using an anti-leukemic drug nilotinib—most ...
Oct 30, 2020
2
66
A new drug designed to work on cancers with an altered BRAF gene has shown promise in an early patient trial presented at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, which is taking place ...
Oct 26, 2020
0
2
A drug combination for people with a rare type of bowel cancer has received an initial rejection from the National Institute for Health and Care Excellence (NICE).
Sep 7, 2020
0
3
(HealthDay)—For patients with stage III melanoma with BRAF V600E or V600K mutations, 12 months of adjuvant dabrafenib plus trametinib results in increased survival without relapse or distant metastasis at five years, according ...
Sep 4, 2020
0
3
